Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its news flow reflects both its operating performance and corporate developments. Company announcements describe technologies that prioritize preservation and restoration of the patient’s own anatomy and leverage the natural healing response while minimizing long-term exposure to permanent synthetic materials.
News updates for TELA stock frequently include quarterly financial results, where the company reports revenue, gross profit, operating expenses, and net loss, along with commentary on demand for its OviTex and OviTex PRS reinforced tissue matrix products. These releases often discuss factors driving revenue, such as increased unit sales, new customers, international sales, and new product configurations, as well as changes in operating expenses and loss from operations.
Investors can also expect capital markets and financing news, including announcements of credit facilities, registered direct offerings of common stock and pre-funded warrants, and the issuance of warrants in connection with debt agreements. Such updates provide insight into TELA Bio’s liquidity, borrowing arrangements, and intended use of proceeds for sales and marketing, research and development, and other corporate purposes.
Another category of TELA Bio news involves corporate governance and leadership changes, such as appointments of new independent directors with experience in healthcare equity research and executive nursing leadership, as well as board resignations. The company also issues releases about participation in healthcare conferences and inducement grants of restricted stock units and stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4).
By following TELA Bio’s news feed, readers gain timely visibility into the company’s financial performance, product demand trends in soft-tissue reconstruction, capital-raising activities, and changes in board composition and employee equity incentives.
TELA Bio, Inc. (NASDAQ: TELA) reported third-quarter 2020 revenues of $5.3 million, a 34% increase year-over-year. This growth was tempered by lower than expected procedural volumes due to COVID-19. Gross profit reached $3.3 million, representing a 62% margin, down from 66% the previous year. Operating expenses rose to $10.2 million, leading to a loss from operations of $6.9 million and a net loss of $7.7 million. The company has $81.5 million in cash. TELA did not provide 2020 financial guidance due to pandemic-related uncertainties.
MALVERN, Pa., Nov. 10, 2020 – TELA Bio, a medical technology company, announced its participation in two investor conferences. Management will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 10:15 AM EST and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 10:30 AM EST. Live audio webcasts will be available on the company’s website. TELA Bio focuses on developing innovative tissue reinforcement materials for soft tissue reconstruction, backed by extensive scientific research.
TELA Bio, Inc. (Nasdaq: TELA), a medical technology firm, will report its 2020 third quarter financial results on November 11, 2020. The company focuses on developing innovative tissue reinforcement materials for soft tissue reconstruction. A conference call will take place at 4:30 p.m. ET on the same day for management to discuss financial results and provide corporate updates. TELA Bio's products aim to improve existing biologics, reducing long-term exposure to synthetic materials, supported by extensive pre-clinical research.
TELA Bio, Inc. announced positive findings from the BRAVO study presented at the Americas Hernia Society Annual Meeting. The data demonstrated a low incidence of surgical site infections and no hernia recurrences at 30 days post-operation using OviTex in ventral hernia repairs. The study involved 85 subjects, with 50% being obese and 16% having a history of surgical infections. Long-term results showed no hernia recurrences among the initial 20 subjects after two years. TELA's OviTex aims to address unmet needs in soft tissue reconstruction.
TELA Bio reported a revenue of $3.5 million for Q2 2020, marking a 6% increase from Q2 2019. Despite this growth, procedural volume declines due to the COVID-19 pandemic impacted results. Gross profit rose to $2.1 million, representing 59% of revenue, up from 58% in the previous year. Operating expenses increased to $7.3 million, leading to a loss from operations of $5.2 million. The company completed a public offering, raising approximately $45 million. Due to COVID-19 uncertainty, TELA will not provide 2020 financial guidance.
TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in tissue reinforcement materials, will participate in the Canaccord Genuity 40th Annual Growth Conference from August 11-13, 2020. Management is set to present on August 13 at 1:30 p.m. ET. The conference will be held virtually, and interested parties can access the live webcast through the company's website. TELA Bio focuses on addressing unmet needs in soft tissue reconstruction with innovative products backed by extensive research.
TELA Bio, Inc. (NASDAQ: TELA) announced it will report its second quarter financial results for 2020 on August 12, 2020. A conference call and webcast led by management will follow at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio specializes in tissue reinforcement materials aimed at soft tissue reconstruction needs, emphasizing the advantages of its products over existing biologics and synthetic materials. The company’s offerings are backed by robust pre-clinical research.
Tela Bio, Inc. has successfully closed its public offering, issuing 3,000,000 shares at $16.00 each, translating to gross proceeds of $48 million before costs. The underwriters have a 30-day option to buy an additional 450,000 shares. Jefferies LLC and Piper Sandler & Co. led the offering management, with a registration statement filed with the SEC now effective. TELA specializes in innovative tissue reinforcement materials aimed at enhancing soft tissue reconstruction, with a focus on minimizing the limitations of existing products.
TELA Bio, Inc. announced the pricing of its underwritten public offering of 3,000,000 shares at $16.00 per share, aiming for gross proceeds of $48 million. The offering includes a 30-day option for underwriters to purchase an additional 450,000 shares. This offering is expected to close on June 30, 2020, pending customary conditions. Jefferies LLC and Piper Sandler & Co. are the book-running managers. TELA focuses on innovative tissue reinforcement materials for soft tissue reconstruction. The registration statement has been effective since June 25, 2020.
TELA Bio, Inc. (TELA) has announced a proposed underwritten public offering of 3,000,000 shares of its common stock, with an option for underwriters to purchase an additional 450,000 shares. The offering is subject to market conditions, and completion is uncertain. Jefferies LLC and Piper Sandler & Co. serve as joint book-running managers. A registration statement was filed with the SEC, but has not yet become effective, meaning sales cannot occur until it does. TELA aims to address unmet needs in soft tissue reconstruction with its innovative materials.